Abstract
There is little data about treatment practices for relapsed/refractory Hodgkin Lymphoma (HL) in nonacademic settings. We describe sequential treatments and outcomes among HL patients who experienced treatment failure in an integrated community-oncology setting. We performed a retrospective cohort study among patients ≥12 years diagnosed with Stage II–IV HL from 2007 to 2012 at Kaiser Permanente Southern California (KPSC). Of 463 HL patients, 75 (16.1%) experienced treatment failure. Patients with failure received between 1 and 8 salvage therapies; 28% received ≥4 lines of therapy. Fifty-nine of 75 (79%) were initially salvaged with ifosfamide-based therapy, 44 of whom underwent hematopoietic cell transplant. Ultimately, 47% of patients died, with most deaths due to HL. Survival was shorter with increasing age at diagnosis (p = 0.02) and with greater number of lines of therapy (p = 0.02). In a community oncology setting, HL patients received multiple lines of salvage. Despite extensive treatment, nearly half of patients died of HL following relapsed/refractory disease.
Keywords:
Disclosure statement
AJK: none; CC: none; AMR: none, AE: Research to Practice (Honoraria); Seattle Genetics (consultancy & honoraria); Pharmacyclics (Honoraria & DMC); Verastem (consultancy & honoraria); Bayer (consultancy & honoraria); Affimed (consultancy & honoraria); Takeda (research funding), Merck (research funding); HC: none; LX: none, SKP: Seattle Genetics (consultancy). No potential conflict of interest was reported by the author(s).
Data availability statement
The data are not available for sharing.